Safety and efficacy of brentuximab vedotin as a treatment for lymphoproliferative disorders in primary immunodeficiencies

Detalles Bibliográficos
Autores principales: Pincez, Thomas, Bruneau, Julie, Berteloot, Laureline, Piekarski, Eve, Thomas, Caroline, Marçais, Ambroise, Trinquand, Amélie, Castelle, Martin, Garcelon, Nicolas, Plantaz, Dominique, Cheminant, Morgane, Moshous, Despina, Molina, Thierry Jo, Hermine, Olivier, Macintyre, Elizabeth, Fischer, Alain, Blanche, Stéphane, Suarez, Felipe, Neven, Bénédicte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2020
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556515/
https://www.ncbi.nlm.nih.gov/pubmed/33054064
http://dx.doi.org/10.3324/haematol.2019.230276

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556515/
https://www.ncbi.nlm.nih.gov/pubmed/33054064
http://dx.doi.org/10.3324/haematol.2019.230276

Ejemplares similares